Cardiac Remodeling and Prognosis in Secondar Tricuspid Regurgitation
NCT ID: NCT03159923
Last Updated: 2023-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2017-01-19
2023-03-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence and Prognostic Relevance of Tricuspid Regurgitation in Different Heart Failure Entities
NCT04570098
Echocardiographic Assessment and CLInical imPlication of Functional tricuSpid rEgurgitation in Heart Failure With Reduced or Preserved Ejection Fraction
NCT05209919
The FUnctional TricUspid REgurgitation by 3D EChocardiography Cooperative Study
NCT05747404
CT Prediction for Transcatheter Tricuspid Interventions
NCT06951126
Measurement of Tricuspid Regurgitation Volume for Assessment of Tricuspid Regurgitation Using 3D Transesophageal Echocardiography
NCT05130775
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients included can be ambulatory patients or stabilized hospitalised patients (meaning patient clinicaly stable, not decompensated, and whose normovolemia has been checked).
* Non opposition of the patient
Exclusion Criteria
* TR \< grade 2 ;
* TR secondary to primary pulmonary hypertension or congenital cardiopathy ;
* Primary tricuspid regurgitation (due to rheumatic heart disease, medication - included benfluorex, due to endocarditis, valvular prolapse, carcinoid syndrom or a cardiac stimulation lead …) ;
* Cardiopathy with significative systolic dysfunction (FE\< 40%) ;
* Patients whose life expectantcy is less than 1 year due to a pathology independent of the TR (neoplasic process for example) ;
* Patient under judicial protection.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erwan DONAL, PhD
Role: PRINCIPAL_INVESTIGATOR
Rennes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Amiens-Picardie - Site Sud
Amiens, , France
Ap-Hp - Hopital Henri Mondor
Créteil, , France
CHU de DIJON - HOPITAL FRANCOIS MITTERAND
Dijon, , France
Chu Grenoble - Michallon
Grenoble, , France
Ghicl - Hopital Saint Philibert
Lomme, , France
Chu Marseille - Hopital Nord
Marseille, , France
Hôpital Saint Joseph
Marseille, , France
Clinique Du Pont de Chaume
Montauban, , France
CLINIQUE du MILLENAIRE
Montpellier, , France
Chu de Nancy - Hopital de Brabois
Nancy, , France
CHU de NANTES - HOTEL DIEU
Nantes, , France
Ap-Hp - Hopital Saint-Antoine
Paris, , France
Chu de Bordeaux - Groupe Hospitalier Sud
Pessac, , France
CHU de Rennes
Rennes, , France
CHU de TOULOUSE - HOPITAL RANGUEIL
Toulouse, , France
Clinique NCT+
Tours, , France
CHU de TOURS - HOPITAL TROUSSEAU
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC16_8919_TRAP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.